Trastuzumabemtansine , ≥98% , 1018448-65-1
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB3840.00 | In Stock |
|
| 5mg | RMB12800.00 | In Stock |
|
| 10mg | RMB20800.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| storage temp. | Store at -20°C |
| form | Solid |
| color | White to off-white |
Description and Uses
T-DM1 is a human epidermal growth factor receptor (HER2)-targeted antibody drug conjugate (ADC) that was approved in February 2013 by the US FDA for use as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer (mBC) who previously received treatment with trastuzumab and a taxane, separately, or in combination. T-DM1 is composed of trastuzumab linked to the potent cytotoxic microtubule polymerization inhibitor DM1 (derivative of maytansine) via a stable uncleavable thioether linker. T-DM1 is produced by chemically crosslinking the cytotoxic maytansinoid derivative to the lysine residues of trastuzumab such that there is an average of 3.5 cytotoxic molecules linked to each antibody. In addition to delivering DM1 to tumor cells, T-DM1 retains the effector functions of trastuzumab, including inhibition of HER2-mediated signal transduction and activation of antibodydependent cell-mediated cytotoxicity.
Safety
| Symbol(GHS) |    GHS08,GHS07,GHS06 |
| Signal word | Danger |
| Hazard statements | H300-H371-H315-H360-H351-H340-H330 |
| Precautionary statements | P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P309+P311-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P201-P202-P281-P308+P313-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501 |
